title: Living related liver transplantation: histopathologic analysis of graft dysfunction in 304 patients.
abstract: Between June 1990 and August 1997, 304 mainly pediatric patients underwent a total of 311 orthotopic living related liver transplantations (LRLTs) under tacrolimus immunosuppression at Kyoto University Hospital. Congenital biliary atresia was the most common underlying disease. The donor was a parent, and the left lateral segments were used as grafts in most cases. The average number of loci of HLA-A, -B, and -DR mismatches between the donor and the recipient were 2.1. Forty-three transplants were ABO-incompatible. Liver histology at the time of abnormal liver function after transplantation was analyzed. Preservation injury was rare and mild. Acute cellular rejection (ACR) occurred in 36% of transplants during the first 6 months. Average rejection activity index (the Banff schema) was 4.2 and severe rejection was rarely seen. The number of mismatching HLA loci and immunosuppression regimens affected the incidence of ACR. Chronic rejection (CR) occurred in 2% of transplants. Concerning humoral rejection, no hyperacute rejection was seen. However, hepatic artery thrombosis (delayed hyperacute rejection) was seen in an ABO-incompatible transplant. Acute hepatitis, including those related to cytomegalovirus and Epstein-Barr virus, occurred in 17% of transplants. Chronic hepatitis, including hepatitis B and C, developed in 3%. Acute or chronic cholangitis occurred in 16%, and a significantly higher incidence of cholangitis was found in ABO-incompatible transplants. Posttransplantation lymphoproliferative disease developed in 2%. In LRLT, milder preservation injury and less frequent ACR and CR were suggested, probably because of the short cold-ischemia time and the advantages of HLA histocompatibility, respectively.
authors.affiliation: Department of Transplantation and Immunology, Kyoto University Hospital, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Minamiguchi
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: S
authors.initials: S
authors.lastname: Fujita
authors.forename: T
authors.initials: T
authors.lastname: Okuno
authors.forename: H
authors.initials: H
authors.lastname: Haga
authors.forename: M
authors.initials: M
authors.lastname: Mino
authors.forename: K
authors.initials: K
authors.lastname: Kanehira
authors.forename: H
authors.initials: H
authors.lastname: Matsushiro
authors.forename: Y
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Y
authors.initials: Y
authors.lastname: Inomata
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Yamabe
mesh_terms: D000293:Adolescent; D000328:Adult; D001787:Blood Group Incompatibility; D002648:Child; D002675:Child, Preschool; D002761:Cholangitis / Q000209:etiology / Q000473:pathology; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000473:pathology; D020031:Epstein-Barr Virus Infections / Q000209:etiology / Q000473:pathology; D005190:Family; D005260:Female; D006084:Graft Rejection / Q000473:pathology*; D006509:Hepatitis B / Q000209:etiology / Q000473:pathology; D006526:Hepatitis C / Q000209:etiology / Q000473:pathology; D006525:Hepatitis, Viral, Human / Q000209:etiology / Q000473:pathology / Q000821:virology; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects; D019520:Living Donors; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014021:Tissue Preservation